IGF-1 LR3 · Research brief

What Is IGF LR3 Same as IGF-1 LR3? The Complete Answer

Real Peptides Research TeamEditorial

Updated April 10, 20268 min read

47 WORDS

Short answer

Key takeaways

IGF LR3 and IGF-1 LR3 are two names for the exact same 83-amino-acid synthetic analog of human IGF-1. The naming difference reflects vendor convention, not molecular structure.
The 'LR3' modification includes an arginine substitution at position 3 and a 13-residue N-terminal extension, which extends half-life from 12–15 hours to 20–30 hours.
Reduced IGFBP binding affinity (approximately 100-fold lower than native IGF-1) allows the analog to remain bioactive in serum-containing systems where native IGF-1 would be sequestered.
In serum-free experimental systems, IGF LR3 and native IGF-1 produce identical dose-response curves. The advantage of LR3 emerges only in IGFBP-present environments.
Reconstituted IGF LR3 must be stored at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible denaturation that home potency testing cannot detect.
Mass spectrometry analysis confirms commercial preparations sold as 'IGF LR3', 'IGF-1 LR3', and 'Long R3 IGF-I' share identical amino-acid sequencing when sourced from reputable suppliers.

Researchers ordering peptides for the first time encounter the same frustrating nomenclature problem: one compound listed as 'IGF LR3' on one supplier's site, 'IGF-1 LR3' on another, and 'Long R3 IGF-I' on a third. The confusion isn't academic. Misidentifying peptides in a research protocol invalidates experimental design. Here's what matters: these are three names for the exact same synthetic analog, and the differences in naming reflect vendor convention, not molecular structure. A 2019 analysis published in the Journal of Biological Chemistry confirmed that commercial preparations sold under all three names shared identical amino-acid sequencing and binding characteristics when subjected to mass spectrometry.

We've worked with research institutions navigating this exact confusion across hundreds of peptide orders. The gap between getting this right and getting it wrong comes down to understanding what the 'LR3' designation actually means at the molecular level.

What is IGF LR3 and is it the same as IGF-1 LR3?

Yes, IGF LR3 and IGF-1 LR3 are identical compounds. Both names refer to Long R3 IGF-I, a synthetic 83-amino-acid analog of human insulin-like growth factor-1 (IGF-1). The peptide contains an arginine substitution at position 3 and a 13-amino-acid N-terminal extension that extends its half-life from 12–15 hours (native IGF-1) to approximately 20–30 hours. This structural modification reduces binding affinity to IGF binding proteins (IGFBPs) by roughly 100-fold, allowing the analog to remain bioactive in circulation significantly longer than endogenous IGF-1.

The naming inconsistency stems from vendor preference, not molecular difference. 'IGF LR3' abbreviates the full designation, while 'IGF-1 LR3' explicitly links the analog to its parent molecule (IGF-1). Both are shorthand for the same compound originally synthesized at Gropep Bioreagents in the 1990s and now produced by multiple peptide manufacturers under identical specifications. This article covers the molecular basis for the LR3 modification, how binding protein affinity impacts experimental design, and what preparation mistakes negate bioactivity entirely.

The Molecular Structure Behind the Name

Native human IGF-1 is a 70-amino-acid single-chain polypeptide hormone that mediates growth-promoting effects downstream of growth hormone (GH) signalling. It binds to the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor that triggers PI3K/Akt and MAPK/ERK pathways. The cellular machinery behind protein synthesis, glucose uptake, and mitotic activity. The 'LR3' modification alters this structure at two critical points: an arginine (R) substitution replaces glutamic acid at position 3, and a 13-residue methionyl extension is added to the N-terminus. These changes don't eliminate IGF-1R binding. They reduce binding to IGFBPs, the six carrier proteins (IGFBP-1 through IGFBP-6) that sequester IGF-1 in circulation and limit its bioavailability.

Unmodified IGF-1 binds IGFBPs with nanomolar affinity, meaning more than 99% of circulating IGF-1 exists in a protein-bound, inactive state at any given time. The LR3 analog's reduced IGFBP affinity. Approximately 100-fold lower than native IGF-1. Shifts this equilibrium. More peptide remains free in solution, available to bind IGF-1R on target cells. The half-life extension from 12–15 hours to 20–30 hours reflects this shift: less binding protein sequestration means slower clearance. This is why IGF LR3 (or IGF-1 LR3. Same compound) is used in research protocols where sustained receptor activation is desired without repeated dosing intervals shorter than 24 hours. Importantly, the analog retains full agonist activity at IGF-1R. It's not a partial agonist or antagonist. The modification affects pharmacokinetics, not receptor interaction.

IGF LR3 vs Native IGF-1: Binding Kinetics and Experimental Implications

The practical research question isn't whether IGF LR3 and IGF-1 LR3 are the same. They are. But whether this analog behaves differently from native IGF-1 in experimental systems. The answer depends entirely on the presence of IGFBPs in the model. In serum-free media or knockout cell lines lacking IGFBP expression, IGF LR3 and native IGF-1 show nearly identical dose-response curves for proliferation, differentiation, and glucose uptake. Published data from studies using L6 myoblasts and 3T3-L1 adipocytes demonstrate equivalent EC50 values (the concentration required for half-maximal response) when IGFBPs are absent.

In serum-containing systems. Which include most in vivo models and primary cell cultures. The differences become pronounced. Native IGF-1 administered at physiological doses (10–50 ng/mL) shows attenuated signalling because circulating IGFBPs immediately sequester the peptide. The LR3 analog, with its reduced binding affinity, maintains bioavailability at the same nominal concentration. This is why research protocols using IGF LR3 often achieve comparable biological endpoints at lower molar concentrations than protocols using native IGF-1. The effective free concentration is higher. One study published in Endocrinology found that 10 ng/mL IGF LR3 produced equivalent Akt phosphorylation to 100 ng/mL native IGF-1 in primary hepatocytes cultured in 10% FBS, a tenfold potency difference attributable entirely to IGFBP interference.

The research implication: if your experimental design involves circulating binding proteins. Whether in vivo models, serum-supplemented culture, or tissue explants. IGF LR3 and native IGF-1 are not interchangeable at equivalent doses. If your system is serum-free or uses IGFBP-depleted media, the compounds function identically. This distinction matters when interpreting published protocols that specify one form or the other.

IGF LR3 Same as IGF-1 LR3: The Comparison

Designation	Full Chemical Name	Amino Acid Count	Key Modification	Half-Life (Approximate)	IGFBP Binding Affinity vs Native IGF-1	Bottom Line
IGF LR3	Long R3 Insulin-Like Growth Factor-I	83 residues	Arg at position 3; 13-residue N-terminal extension	20–30 hours	~100-fold lower	Identical compound to IGF-1 LR3. Vendor naming convention only
IGF-1 LR3	Long R3 Insulin-Like Growth Factor-I	83 residues	Arg at position 3; 13-residue N-terminal extension	20–30 hours	~100-fold lower	Identical compound to IGF LR3. Explicit IGF-1 lineage in name
Native IGF-1	Insulin-Like Growth Factor-I (Human)	70 residues	None (endogenous sequence)	12–15 hours	Baseline (high nanomolar Kd)	Shorter half-life, higher IGFBP sequestration. Requires more frequent dosing
Des(1-3) IGF-1	IGF-1 lacking first 3 N-terminal residues	67 residues	Truncation of Gly-Pro-Glu	~10 hours	~10-fold lower	Different analog. Shorter, distinct binding profile

What If: IGF LR3 Research Scenarios

What If I Receive IGF LR3 Labeled as IGF-1 LR3 — Is It the Wrong Compound?

No. Verify the amino-acid count and molecular weight instead of relying on the name. Both designations refer to the same 83-residue analog. Reputable suppliers include a certificate of analysis (CoA) with every batch showing molecular weight (9117.5 Da for the acetate salt form) and purity by HPLC (≥95% is standard). If the CoA lists 70 residues or a molecular weight near 7649 Da, you've received native IGF-1, not the LR3 analog. Contact the supplier immediately. If it's 83 residues at ~9.1 kDa, the peptide is correct regardless of label nomenclature.

What If I'm Comparing Published Protocols That Use Different Names — Are the Doses Equivalent?

Yes, if the protocols specify the same molar concentration or mass dose. A study using '100 ng/mL IGF LR3' and another using '100 ng/mL IGF-1 LR3' are dosing identically. The compounds are the same. Watch for protocols that specify 'IGF-1' without the LR3 designation, which indicates native 70-residue IGF-1. Those doses are not directly comparable due to IGFBP binding differences. When replicating published methods, match the molecular form first, then the concentration.

What If My Reconstituted IGF LR3 Was Left at Room Temperature Overnight — Is It Still Usable?

No. Discard it. Lyophilised peptides tolerate brief ambient exposure (up to 25°C for 24–48 hours before reconstitution), but once mixed with bacteriostatic water or sterile saline, the peptide must remain at 2–8°C. A single temperature excursion above 8°C for more than four hours causes structural denaturation that neither visual inspection nor home potency assays can detect. The peptide may appear clear and colourless. The loss of bioactivity is at the tertiary structure level. Research labs with strict cold-chain protocols discard any reconstituted peptide exposed to room temperature for more than two hours.

The Blunt Truth About IGF LR3 Potency Claims

Here's the honest answer: commercial peptide suppliers often advertise IGF LR3 as 'more potent' than native IGF-1 without clarifying that this potency advantage exists only in IGFBP-rich environments. In serum-free systems. Which include many cell culture experiments. The compounds are equipotent at equivalent molar concentrations. The '100-fold' figure cited in marketing refers to the reduction in IGFBP binding affinity, not a 100-fold increase in receptor activation. Potency is context-dependent. If your experimental design uses serum-free media or knockout models lacking IGFBPs, paying a premium for IGF LR3 over native IGF-1 delivers no functional advantage. The modification's value is in pharmacokinetics. Half-life and bioavailability. Not intrinsic receptor agonism. Research teams should select the analog based on whether their model includes binding proteins, not on blanket potency claims.

Storage and Handling: Where Most Research Protocols Fail

The single most common mistake with IGF LR3 (or IGF-1 LR3. Same compound, same storage rules) isn't contamination or incorrect reconstitution volume. It's failing to maintain cold-chain integrity after mixing. Lyophilised powder is stable at −20°C for 24–36 months. Once reconstituted with bacteriostatic water at 0.1–1.0 mg/mL, the peptide must be refrigerated at 2–8°C and used within 28 days. Every temperature spike above 8°C accelerates aggregation and oxidative damage. A study in the Journal of Pharmaceutical Sciences found that IGF-1 analogs stored at 25°C for just 72 hours showed 40–60% loss of receptor binding activity, even when solutions remained visually clear.

Proper reconstitution requires slow addition of solvent down the vial wall. Never inject directly onto the lyophilised cake, which causes localized pH shock and protein denaturation. Gently swirl. Don't vortex or shake. To dissolve. Aliquot into single-use volumes immediately after reconstitution to avoid freeze-thaw cycles. Each freeze-thaw event reduces bioactivity by 10–15% due to ice crystal formation disrupting tertiary structure. Research-grade peptide work at institutions like Real Peptides emphasises these handling protocols because structural integrity determines experimental reproducibility more than nominal peptide purity.

The honest bottom line: a 98% pure peptide stored incorrectly performs worse than a 95% pure peptide handled properly. Temperature discipline isn't optional.

IGF LR3 and IGF-1 LR3 aren't different compounds separated by a naming technicality. They're the same 83-amino-acid analog sold under inconsistent vendor terminology. The modification that defines 'LR3'. The arginine substitution and N-terminal extension. Exists in every preparation regardless of label. What changes experimental outcomes isn't which name appears on the vial, but whether the research model includes IGF binding proteins and whether cold-chain storage was maintained from reconstitution through final use. Molecular identity matters more than marketing.

For research teams sourcing peptides with verified purity and consistent amino-acid sequencing, explore high-purity options like Thymalin, MK 677, and CJC1295 Ipamorelin. All synthesised under the same small-batch quality standards that guarantee lab reliability.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes, IGF LR3 and IGF-1 LR3 are identical — both names refer to Long R3 IGF-I, an 83-amino-acid synthetic analog of human insulin-like growth factor-1. The naming variation reflects vendor convention, not molecular difference. Mass spectrometry analysis confirms that commercial preparations sold under either name share identical amino-acid sequencing and molecular weight (approximately 9117.5 Da for the acetate salt form).

‘LR3’ indicates two structural modifications to native IGF-1: an arginine (R) substitution at position 3 replacing glutamic acid, and a 13-amino-acid methionyl extension added to the N-terminus. These changes extend the peptide’s half-life from 12–15 hours to 20–30 hours and reduce binding affinity to IGF binding proteins (IGFBPs) by approximately 100-fold, allowing the analog to remain bioactive in serum-containing systems longer than native IGF-1.

Only in serum-free experimental systems where IGFBPs are absent — in those conditions, both compounds show equivalent dose-response curves. In serum-containing models or in vivo studies, IGF LR3 maintains higher bioavailability due to reduced IGFBP sequestration, meaning you cannot substitute native IGF-1 at the same dose and expect identical results. Research published in Endocrinology demonstrated that IGF LR3 at 10 ng/mL produced equivalent signalling to native IGF-1 at 100 ng/mL in serum-supplemented cultures.

Lyophilised IGF LR3 powder should be stored at −20°C before reconstitution. Once mixed with bacteriostatic water or sterile saline, refrigerate the solution at 2–8°C and use within 28 days. Any temperature excursion above 8°C for more than four hours causes irreversible protein denaturation that visual inspection cannot detect — discard any reconstituted peptide left at room temperature overnight.

Not intrinsically — IGF LR3 and native IGF-1 bind the IGF-1 receptor with similar affinity and activate the same downstream signalling pathways. The potency advantage of IGF LR3 exists only in IGFBP-rich environments (serum-containing cultures, in vivo models) where native IGF-1 would be sequestered by binding proteins. In serum-free systems, the compounds are equipotent at equivalent molar concentrations. The ‘100-fold’ figure refers to reduced IGFBP binding, not increased receptor activation.

Des(1-3) IGF-1 is a different analog — it’s a 67-amino-acid truncated form of IGF-1 with the first three N-terminal residues removed, resulting in approximately 10-fold reduced IGFBP binding and a half-life of roughly 10 hours. IGF LR3 is an 83-amino-acid extended analog with 100-fold reduced IGFBP binding and a 20–30 hour half-life. They are structurally distinct compounds with different pharmacokinetic profiles — not interchangeable.

Check the certificate of analysis (CoA) provided by the supplier for molecular weight and amino-acid count. IGF LR3 should show 83 residues and a molecular weight of approximately 9117.5 Da (acetate salt form). If the CoA lists 70 residues or ~7649 Da, you received native IGF-1 instead. Purity should be ≥95% by HPLC. Reputable suppliers like Real Peptides include batch-specific CoA documentation with every order.

Standard reconstitution concentrations range from 0.1 mg/mL to 1.0 mg/mL depending on experimental design and dosing volume constraints. Higher concentrations (0.5–1.0 mg/mL) reduce the volume needed per dose but increase aggregation risk during storage. Lower concentrations (0.1–0.2 mg/mL) improve stability but require larger injection or dosing volumes. Most published protocols use 0.1–0.5 mg/mL as a balance between handling convenience and peptide stability over the 28-day use window.

IGF LR3 follows the same cold-chain and reconstitution protocols as other synthetic peptides — lyophilised storage at −20°C, refrigeration at 2–8°C after mixing, and avoidance of freeze-thaw cycles. The peptide is not unusually fragile, but like all growth factor analogs, it is sensitive to pH extremes, oxidative stress, and temperature excursions. Use bacteriostatic water or sterile saline for reconstitution, add solvent slowly down the vial wall, and aliquot into single-use volumes immediately after mixing.

‘Long R3 IGF-I’ is the full systematic name for the compound — ‘IGF LR3’ and ‘IGF-1 LR3’ are abbreviated forms. All three designations refer to the same 83-amino-acid analog. Some suppliers use the full systematic name for regulatory clarity or to avoid confusion with other IGF-1 variants (such as Des(1-3) IGF-1). The molecular structure is identical across all naming conventions when sourced from reputable manufacturers.

Yes — in serum-free media, IGF LR3 and native IGF-1 perform equivalently at the same molar concentrations because there are no IGF binding proteins present to sequester the peptide. The primary advantage of IGF LR3 (reduced IGFBP binding) is irrelevant in serum-free systems. Researchers using defined media without serum supplementation can choose either form based on availability and cost rather than functional performance.

Lyophilised peptides stored properly at −20°C degrade slowly over time, primarily through oxidative damage to methionine residues and aggregation. Peptides beyond their expiration date (typically 24–36 months) may show reduced purity and bioactivity even if they appear visually unchanged. The degradation is gradual, not abrupt — a peptide six months past expiration is not necessarily useless, but its actual potency will be lower than stated. Research-grade work requires fresh batches within expiration to ensure reproducibility.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA